The poster is scheduled for presentation on May 31, 2025, from 01:30pm to 04:30pm CDT in the Lung Cancer track.

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting Provided by Business Wire May 15, 2025, 3:05:00 PM ...

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics MAIA seeks to advance two new THIO-derived telomere ...

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell ...

Abstracts related to the EACR meeting will be published online following the presentation. For more information, please visit the EACR 2025 website. Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a ...

IO Biotech has deployed its unique approach to modulate TGFb1 activity in the TME, and the poster details the identification and characterization of highly selective TGFb1 peptide vaccines.

CHICAGO, May 15, 2025--MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

MAIA Biotechnology, Inc.,, a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract about its Phase 2 THIO-101 clinical trial ...

Log in MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 Mar. 25, 2025 8:46 AM ETMAIA Biotechnology, Inc. (MAIA) Q4: 2025-03-21 Earnings Summary ...